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Edited by Robert Russell and Giulio Superti-FurgaAbstract It is now widely accepted that cancer is a genetic dis-
ease and that alterations in the DNA sequence underlie the devel-
opment of every neoplasm. The identiﬁcation of mutated genes
that are causally implicated in oncogenesis (cancer genes) has
been a major goal in medical sciences for the last two decades.
The availability of the human genome sequence coupled to the
introduction of high throughput sequencing technologies has cre-
ated an unprecedented opportunity in this ﬁeld. It is now possible
to perform mutational studies of entire cancer genomes thus pro-
viding a complete description of mutations underlying human
oncogenesis. The recent identiﬁcation of high frequency muta-
tions in the BRAF and PI3K genes suggests that many more can-
cer genes remain to be discovered. In this review, we consider
how the systematic mutational analysis of gene families in indi-
vidual neoplasms has led to the identiﬁcation of a number of can-
cer genes and how this information is inﬂuencing the treatment of
cancer.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In the living cell, DNA undergoes frequent chemical changes.
The majority of these changes are quickly repaired; those that
are not result in a mutation. Cancer progression results by
the serial accumulation of genetic accidents in somatic cells [1].
The genes that are causally involved in oncogenesis are
known as cancer genes. DNA alterations that convey tumor-
associated properties are favored by natural selection that ulti-
mately drives the acquisition of the neoplastic properties [2].
Initially, these involve the deregulation of proliferation and
resistance to apoptosis. Subsequently, some cancer cells ac-
quire the ability to invade and colonize other tissues giving rise
to metastasis that are primarily responsible for cancer-associ-
ated mortality.
A primary way to discriminate whether a mutated gene plays
a causal role in cancer progression is that the presence of muta-
tions in the gene, rather than being attributable to chance, are
thought to result in a growth advantage on the cell population
from which the cancer developed [3].*Corresponding author.
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doi:10.1016/j.febslet.2005.02.015Since the ﬁrst speculations on their existence, more than 100
cancer genes have been identiﬁed [4]. However, even com-
monly mutated cancer genes have remained undetected until
very recently. For example, only in the last 3 years the BRAF
[5] and the PI3K [6,7] genes have been shown to be frequently
mutated in a large fraction of tumors and to play a causative
role in tumorigenesis. It is therefore reasonable to assume that
many more cancer genes remain to be identiﬁed.2. Cancer genes discovery and the human genome project
A simplistic interpretation divides cancer genes into three
broad categories: oncogenes, tumor suppressors and stability
genes. Oncogenes promote cell growth and when mutated re-
sult in constitutively or abnormally active proteins; such muta-
tions are mainly of the dominant type. Tumor suppressors
genes are negative controllers of cell cycle progression and
the mutations that aﬀect them are typically recessive. A third
category of cancer genes has been proposed more recently.
This comprises the so-called stability or caretaker genes. These
genes are not directly involved in tumorigenesis but when al-
tered they contribute to cancer by exposing cells to an abnor-
mally high mutation rate. This feature ultimately leads to
oncogene activation or tumor suppressor inactivation. Regard-
less of the speciﬁc genes involved, the end result of the molec-
ular alteration aﬀecting cancer genes is the deregulation of
cellular homeostasis [8,9].
As human cancer is a genetic disease, the completion of the
human genome project has oﬀered unprecedented opportuni-
ties for cancer diagnosis, prognosis and treatment. The ﬁeld
of cancer genes discovery has been one of the ﬁrst to be aﬀected
by this historic revolution that will ultimately allow the identi-
ﬁcation of all genetic alterations underlying the origin and evo-
lution of tumors. Below we consider how systematic mutational
analysis of gene families in individual neoplasms has led to the
identiﬁcation of a number of cancer genes and how this infor-
mation has already aﬀected the treatment of cancer.3. Discovery of cancer genes before the human genome project
3.1. The oncogeness hunt
Until the completion of the human genome project a number
of approaches have led to the identiﬁcation of genes that when
mutated are causally implicated in oncogenesis.
Key breakthrough in the discovery of oncogenes resulted
from studies on retroviruses. Retroviruses are RNA tumorblished by Elsevier B.V. All rights reserved.
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ome can be retrotranscribed into DNA. They can be di-
vided into two groups: acute transforming and weakly
oncogenic retroviruses [10]. The former induce tumor for-
mation very rapidly (days) after infection and were found
to contain modiﬁed copies of cellular genes that have been
incorporated into the viral genome during retroviral trans-
duction process. Rous and colleagues obtained key clues
on acute transforming oncogenes in 1911. For the ﬁrst time
they reported that sarcomas could be induced in chickens
by cell free ﬁltrates of a sarcoma taken from another
chicken. However, the region responsible for the oncogenic-
ity was isolated only 60 years later. It was v-src, a mutated
copy of the human c-src gene [11]. The weakly oncogenic
retroviruses cause tumors only after a long incubation per-
iod (months). Contrary to acute transforming retroviruses,
weakly oncogenic retroviruses do not contain viral onco-
genes. They were also central in the identiﬁcation of cancer
genes. In fact, weakly oncogenic retroviruses induce tumors
via a process called insertional mutagenesis. Speciﬁcally,
they integrate in the host genome close to an oncogene thus
ensuing its abnormal expression which is typically driven by
the transactivating elements contained in the virus genome
[12,13].
In addition to the studies on retroviruses, pioneer exper-
iments designed to identify dominant mutations were intro-
duced at the beginning of the 1980s together with the
advancement of cell transfection techniques [14,15]. In par-
ticular a speciﬁc oncogene hunting technique (known as the
‘‘NIH 3T3 transformation assay’’) was established. This
technique is based on the extraction of genomic DNA
from tumor samples that is fractionated and then intro-
duced into NIH 3T3 mouse ﬁbroblasts. If an oncogene is
present colonies of hyper proliferating cells appear in the
cell culture. Each colony is generated from the clonal
expansion of a single cell, which gained a proliferative
advantage after ectopic gene expression and as a result
has lost the cell–cell contact inhibitory control mechanisms.
The process is then serially repeated by extracting the
genomic DNA from the transformed foci ultimately leading
to the identiﬁcation of the human gene responsible for the
tumorigenic properties.
Several oncogenes have been discovered using the NIH
3T3 transformation assay. The methodology was initially
applied to a human bladder carcinoma cell line [16,17]
and has lead to the identiﬁcation of one of the most com-
mon genetic lesions found in a variety of cancers. In the
speciﬁc case, the genetic alteration turned out to be a single
point mutation which resulted in the incorporation of Valine
instead of Glycine as the 12th amino acid residue in the Ras
protein [18]. hRas mutations are present in more than 25%
of all human cancers. hRas encodes for small monomeric
GTPases responsible for delivering external signals captured
by the cells via their membrane receptors to the cell nucleus.
The point mutations aﬀecting hRas generate a protein,
which fails to eﬃciently hydrolyze GTP and therefore re-
mains constitutively active resulting in deregulated cellular
proliferation.
Signiﬁcant improvements in the identiﬁcation of oncogenes
also stemmed from the karyotypic analysis of human cancers.
In particular, tumors of the haematopoietic system such as leu-
kemias were shown to carry speciﬁc chromosomal transloca-tions. The introduction of sophisticated chromosomal
banding techniques at the beginning of the 1970s allowed the
precise description of those changes. Breakpoints (both trans-
locations and inversions), ampliﬁcations and deletions were
then characterized in detail [19]. A classical example of the
power of this strategy is the identiﬁcation of the genetic alter-
ation responsible for chronic myeloid leukemia (CML). In this
case, karyotype analysis unequivocally determined that cells of
patients aﬀected by CML are characterized by a translocation
between chromosomes 9 and 22 (t(9;22)(q34;q11)) [20]. The
translocation generates the Philadelphia chromosome. In this
chimeric chromosome, the 5 0 segment of the BCR gene is jux-
taposed to the 3 0 region of the ABL gene and results in a con-
stitutively active 210 kDa fusion protein: the tyrosine kinase
BCR-ABL [21].3.2. The tumor suppressor’s hunt
The behavior of cancer cells suggested that not all tumor
properties could be explained by the deregulated over activa-
tion of oncogenes, but the inactivation of other genes was
also crucial. Mutations aﬀecting tumor suppressor genes typ-
ically reduce or abolish the activity of the corresponding
protein product. Examples are missense mutations at resi-
dues that are essential for the catalytic activity, mutations
that result in a truncated protein, deletions or insertions of
various sizes and epigenetic silencing. Usually, it is necessary
to eliminate both copies of a tumor suppressor gene to inac-
tivate it.
Identiﬁcation of genes inactivated during tumorigenesis is
a challenging task. An important contribution to the identi-
ﬁcation of tumor suppressor genes was made by Harris and
colleagues [22]. Using cell fusion experiments they observed
that growth of murine tumors in synergic animals could
be suppressed when malignant cells were fused to non-malig-
nant cells. Moreover, it was found that tumorigenicity was
associated with speciﬁc chromosomal losses and that
the introduction of single chromosomes could reverse
malignancy.
A breakthrough in the discovery of the ﬁrst tumor sup-
pressor gene came from retinoblastoma, a rare tumor that
occurs in childhood. This tumor develops from neural pre-
cursor cells in the immature retina, usually sporadically,
but in some families, it displays an autosomal dominant
mode of inheritance [23]. In the hereditary type, multiple tu-
mors occur independently, aﬀecting both eyes. In the spo-
radic form only one eye is aﬀected, and by only one
tumor. A key clue on the putative gene responsible for reti-
noblastoma was obtained when the karyotype of patients
with the inherited form was shown to be abnormal. The
karyotype was characterized by a deletion of chromosome
13 band q14 [24,25]. Deletions of the same locus were also
observed in tumor cells from patients aﬀected by the non-
hereditary form, suggesting that the cancer was possibly
caused by loss of a critical gene located in that particular
chromosomal region. Subsequently, the locus was character-
ized in detail and the Rb gene was identiﬁed. Loss of Rb is
one of the crucial steps in cancer progression. The Rb gene
encodes the Rb protein, a key regulator of the cell cycle.
pRb undergoes cell-cycle dependent phosphorylation, which
is dependent on the activity of several cyclin-dependent ki-
nases and occurs in a stepwise manner [26]. When hypo-
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family of transcription factors. Upon progression through
the cell cycle pRB becomes hyperphosphorylated and there-
fore releases E2F factors which, in turn, transactivate genes
containing E2F recognition sites in their regulatory sequences
[26]. Rb mutations are thought to inﬂuence the stability of
the genome of cancer cells.4. Discovery of cancer genes after the human genome project
The completion of the human genome and the introduction
of high throughput sequencing technologies allow the discov-
ery of cancer genes through systematic approaches. In princi-
ple, it is now possible to sequence every gene in a given
cancer genome and identify every mutation.
Already, a number of laboratories have started the system-
atic mutational proﬁling of cancer genomes. In order to
achieve this goal a new generation of bioinformatic tools has
been developed to extract exonic and intronic sequences for
each gene of interest from the available databases. The se-
quences are then exploited for high throughput design of exon
speciﬁc ampliﬁcation and sequencing primers. Automated pro-
cedures for ampliﬁcation and direct sequencing of exons from
tumour derived genomic DNA have also been implemented
[5,27]. These require robotic handling of PCRs, puriﬁcation
and sequencing of PCR products. Speciﬁc mutational analysis
algorithms have made it possible to identify both heterozygous
and homozygous mutations in high throughput fashion (Fig.
1). Using softwares programs based on these algorithms high
throughput mutational analysis can be achieved by comparingFig. 1. Strategies for the systematic identiﬁcation of cancchromatograms from diﬀerent tumors to a reference sequence
[27].
4.1. Discovery of cancer genes by dissecting oncogenic signal
pathways
Among the strategies devised to identify cancer genes in the
post genomic era a genetic analysis was implemented by Da-
vies and colleagues [5] to identify cancer-associated mutations
by dissecting signaling pathways. Speciﬁcally, they decided to
search for mutations in members of signaling pathways known
to involve at least one gene previously found mutated in hu-
man cancers. They started by analyzing all the members of
the RAS–RAF–MEK–ERK–MAP kinase pathway [5,28]. In
this approach the initial high throughput screening for muta-
tions was achieved using a capillary-based heteroduplex tech-
nology and not by the direct comparison of DNA sequence
traces. The second approach was implemented later and, given
its better performance, is currently the standard for large scale
sequencing projects [27].
Using this strategy, the authors reported genetic alterations
in the BRAF gene in a variety of cancers, in particular in 66%
of malignant melanomas analyzed [5]. Further, using the cano-
nic transformation assay they conﬁrmed that the mutations
ultimately result in hyperactive proteins capable of transform-
ing NIH 3T3 cells. Mutations in BRAF have later been found
in a variety of cancers. Interestingly, mutations in genes within
this signal transduction cascade are mutually exclusive as
BRAF mutations occur only in tumors that are not aﬀected
by a mutation in hRas and vice versa [28]. The work by Davies
and colleagues clearly showed that despite decades of research
in the ﬁeld even common genetic alterations had remaineder genes by mutational proﬁling of tumor genomes.
Table 1
Selected list of kinase genes genetically altered in human cancers
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of cancer genomes [5].Gene Tumor Mutation
ABL CML, ALL T
AKT2 Ovarian, pancreatic A
BRAF Melanoma, colon M
EGFR Glioma, NSCL M, D
EPHA3 Colon M
ERBB2 Breast, ovarian, NSCL M, A
FES Colorectal M
FGFR2 Gastric M
FGFR3 Bladder, MM M, T
FLT3 AML, ALL M
GUCY2F Colorectal M
JAK2 AML, ALL T
KIT GIST, AML M
MET Renal, HCC, colon M, A
MLK4 Colon M, N
NTRK1 Thyroid T
NTRK2 Colon M
NTRK3 Fibrosarcoma, breast (Secretory), colon T, M, N
PDGFRA GIST M
PIK3CA Colon, brain, breast, colorectal, brain M, A
RET Thyroid, MEN M,T
Alterations are in roman or italic if they were identiﬁed before or after
the genome revolution respectively. AML, acute myelogenous leu-
kaemia; MM, multiple myeloma; ALL, acute lymphocytic leukaemia
GIST, gastrointestinal stromal tumour; MEN, multiple endocrine
neoplasia; HCC, hepato-cellular carcinoma; NSCL, non-small-cel
lung; M, missense mutation; T, translocation; N, non-sense mutation
D, deletion and A, ampliﬁcation.
Table 2
Selected list of phosphatase genes genetically altered in human cancers4.2. Discovery of cancer genes by mutational proﬁling of gene
families
So far, the most eﬃcient approach for the identiﬁcation of
cancer genes in the post-genomic era has proven to be the sys-
tematic mutational proﬁling of gene families [27]. Genes can be
categorized into families using diﬀerent criteria [3]. Sequence
regions similar to one another are typically translated into pro-
tein domains with similar biochemical properties, which in
turn reﬂect overlapping function. Using this approach, it is
therefore possible to predict all the genes with similar function
present in the genome. Members of the same gene family can
substitute one another in executing cellular functions as it
has been shown in model organisms such as Drosophila mela-
nogaster and Caenorhabditis elegans. Therefore, from a genetic
perspective, the analysis of an entire gene family allows to sys-
tematically evaluate the relevance of a speciﬁc biochemical
function, for example the phosphorylation of tyrosine residues
in a given organism or cell type [29,30]. The parallel analysis of
all genes controlling the execution of a particular biochemical
reaction is especially appealing in cancer genetics [3]. If there is
redundancy, only the simultaneous analysis of all the genes
that can perform a speciﬁc reaction can identify which member
is altered in a given tumor. If the mutated genes have overlap-
ping functions or act within the same signaling pathways, the
mutations will be mutually exclusive thus providing additional
information on the model [28].Gene Tumor Mutation
PTEN Glioma, prostate, endometrial D, M, N
PTPN3 Colon M, N
PTPN13 Colon M, N, D
PTPN14 Colon M
PTPRF Colon, breast, lung M
PTPRG Colon M
PTPRT Colon, gastric, lung M, N, D
Shp2/PTPN11 JMML, AML, MDS M
Alterations are in roman or italic if they were identiﬁed before or after
the genome revolution respectively. JMML, juvenile myelomonocytic
leukaemia; AML, acute myelogenous leukaemia; MDS, myelodys-
plastic syndrome; M, missense mutation; T, translocation; N, non-
sense mutation and D, deletion.5. Analysis of the kinome and the phosphatome in cancers
As previously stated cancer is a genetic disease caused by
mutations in oncogenes, tumor suppressor or stability genes.
Regardless of the speciﬁc genes involved, the ﬁnal consequence
of the molecular alteration aﬀecting cancer genes is the dereg-
ulation of cell proliferation and cell death rate [8,9]. Many of
the molecules in charge of controlling cellular homeostasis
are switched on and oﬀ by the addition and removal of phos-
phate groups. This ultimately determines the relocalization
and/or the activation of the downstream eﬀectors thus result-
ing in the biological output.
Ultimately, the phosphorylation state of a cellular molecule
results from the balanced activity of kinases, responsible for
adding the phosphate residues, and phosphatases, in charge
of removing the phosphate groups [31,32]. Both these gene
families are central in signaling pathways involved in tumori-
genesis. Interestingly, in spite of their importance, many ki-
nases and most phosphatases have not been studied in detail
until very recently.
Kinases and phosphatases are characterized by the presence
of speciﬁc regions in their sequences known as kinase and
phosphatase domains. Exploiting bioinformatic tools such as
Hidden Markov models it is possible to identify all the genes
belonging or closely related to each of these two families. Re-
cently, the ﬁrst genome wide mutational analyses of entire gene
families were completed in colorectal tumours (Tables 1 and
2). These included the tyrosine kinases (tyrosine kinome) [27],
the lipid kinases (lipid kinome) [7] and the tyrosine phospha-
tases (tyrosine phosphatome) [33]. A more limited analysis;
l
;involving mainly tyrosine kinases receptors was also completed
in non small cell lung cancers (NSCLC) [34]. Overall such
genomic analyses have already demonstrated their utility in ba-
sic and clinical cancer research. For example, the systematic
sequencing of gene families in colorectal cancers allowed the
identiﬁcation of mutations in 8 kinase and 6 phosphatase genes
(Tables 1 and 2). Thus showing that more than 50% of colorec-
tal cancers carry a mutation in a kinase or phosphatase gene
[7,27,33]. Among the genes identiﬁed by this approach was
PI3K, which is mutated not only in colorectal but also in
breast, brain, gastric, lung and other tumor types. The fre-
quency of mutations in the PI3KCA gene makes it one of
the most commonly mutated oncogenes in human cancer.
On the other end, the systematic mutational proﬁling of
tyrosine kinases in NSCL cancers led to the discovery that clin-
ical response to the EGFR small molecule inhibitor geﬁtinib
was associated to activating mutations in the EGFR gene
[34–37, see also further details below].
1888 S. Benvenuti et al. / FEBS Letters 579 (2005) 1884–1890Several conceptual implications can be drawn from the sys-
tematic mutational analysis of the kinome and phosphatome in
colorectal cancers. The ﬁrst is that the type of somatic muta-
tions observed appears to be at least in part gene-family spe-
ciﬁc. For example, kinases tend to be altered by
heterozygous missense mutations that mainly aﬀect residues
involved in the control of the catalytic activity. This suggests
that the mutations are activating and operate by increasing
the enzymatic activity of the corresponding proteins. This also
implies that altered kinase genes mainly act as dominant onco-
genes. On the other hand, tyrosine phosphatases are frequently
altered by nonsense mutations that often aﬀect both alleles.
This suggests that the mutated phosphatase genes could act
as tumor suppressors.
The mutational proﬁling of the kinome and phosphatome
also show that a relatively small number of genes are aﬀected
by somatic mutations, even in gene families that are thought to
play a central role in tumorigenesis. This is diﬀerent from what
is obtained by the systematic analysis of gene expressionFig. 2. Examples of targeted cancer therapies based on protein kinases inhwhereby large sets of genes are typically found to be diﬀeren-
tially expressed between normal and neoplastic tissues. Impor-
tantly, somatic mutations that have been selected during
tumorigenesis are by deﬁnition causally related to tumor for-
mation while in many cases the genes identiﬁed during diﬀeren-
tial gene expression studies are not.
As discussed above the technological advances and the avail-
ability of the genome sequence make it possible to identify all
the genes altered by somatic mutations in human cancers. Gi-
ven that mutations appear to represent legitimate targets for
anti-cancer drugs (see below) the mutational analysis of can-
cers should be expanded to include other gene families that
could be suitable for therapeutic targeting. Among those are
the serine/threonine kinases, the genes involved in G protein
signaling and transcription factors genes. In addition, the sys-
tematic mutational analysis of the kinome and phosphatome
have so far been completed only in a fraction of cancers and
therefore these families remain to be analyzed in many tumor
types.ibitors tailored to speciﬁc genetic lesions underlying drug sensitivity.
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cancer therapies
Cancer treatments have signiﬁcantly improved in the last
decade and the discovery that cancer is a genetic disease has
played a central role in this revolution. Somatic mutations that
have been selected during tumorigenesis are, by deﬁnition,
causally related to tumor formation and therefore represent
legitimate targets for anti-cancer drugs. For quite some time
this seemingly obvious paradigm has been somewhat ne-
glected. Only recently the genetic proﬁling of cancers has
achieved a central role in the development of new drugs and
in the selection of the patients who are likely to beneﬁt from
them [38]. Recent exciting results showing that therapeutic tar-
geting is more eﬀective in the context of somatic genetic alter-
ations have been instrumental in this process. Compounds
targeting protein tyrosine kinases are among those shown to
achieve the most dramatic eﬀect when tailored to cancers dis-
playing speciﬁc genetic alterations (Fig. 2). For example, the
treatment of chronic myeloid leukemia (CML) [39,40] and of
advanced gastrointestinal stromal tumors (GISTs) [41] has
changed since the introduction of imatinib. Imatinib mesylate,
initially known as STI571 and commercialized as Gleevec, was
developed to inhibit the Bcr-Abl protein. It also inhibits sev-
eral other tyrosine kinases (TK) including the transmembrane
receptor KIT [42,43] and the platelet-derived growth factor
receptor (PDGFR). Remarkably, the often dramatic response
of GIST patients to imatinib was shown to be associated with
the mutational status of the KIT and PDGFR receptors in the
corresponding tumors [44] (Fig. 2).
Another notable example of cancer therapy tailored on the
basis of a speciﬁc genetic alteration is treatment of recurrent
breast cancers. In this case, trastuzumab (Herceptin) a mono-
clonal antibody directed against the extracellular domain of
the HER-2 receptor is mainly eﬀective in patients with ampliﬁ-
cation of the HER-2 gene [45]. The last and more recent exam-
ple is the treatment of NSCL cancer, here the presence of
activating mutations aﬀecting the EGFR gene was found to
underlie the response to geﬁtinib (Iressa) [34–37] (Fig. 2).
The tailored treatment of cancer patients based on the mu-
tated genes present in their tumors is revolutionizing the clinical
oncology ﬁeld. The systematic mutational proﬁling of cancer
genomes is a key aspect of this process and will undoubtedly
open up new diagnostic and therapeutic possibilities.
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